Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression.

Montani M, Hermanns T, Müntener M, Wild P, Sulser T, Kristiansen G.

Virchows Arch. 2013 Apr;462(4):437-43. doi: 10.1007/s00428-013-1390-8. Epub 2013 Mar 16. Erratum in: Virchows Arch. 2013 Jul;463(1):99. Herrmanns, Thomas [corrected to Hermanns, Thomas].

PMID:
23503867
2.

Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.

Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, Horvath LG.

Prostate. 2008 Sep 15;68(13):1421-9. doi: 10.1002/pros.20809.

PMID:
18615486
3.

Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.

Cai C, Omwancha J, Hsieh CL, Shemshedini L.

Prostate Cancer Prostatic Dis. 2007;10(1):39-45. Epub 2006 Sep 26.

PMID:
17003774
5.

Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.

Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, Petrovics G.

Clin Cancer Res. 2008 Feb 1;14(3):758-63. doi: 10.1158/1078-0432.CCR-07-1356.

6.

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.

Mod Pathol. 2012 Mar;25(3):471-9. doi: 10.1038/modpathol.2011.176. Epub 2011 Nov 11.

7.

FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.

Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G.

Am J Pathol. 2012 Feb;180(2):848-61. doi: 10.1016/j.ajpath.2011.10.021. Epub 2011 Dec 2.

PMID:
22138582
8.

Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.

Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL.

Cancer Res. 2001 Jan 15;61(2):423-7.

9.

Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.

Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ.

Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23.

PMID:
15196705
10.

Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.

Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN.

Br J Cancer. 2001 Dec 14;85(12):1928-36.

11.
12.

Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R.

Oncol Rep. 2010 Apr;23(4):1045-52.

PMID:
20204290
13.

Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines.

Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF.

J Biol Chem. 1998 Mar 6;273(10):5939-47.

14.
15.

An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.

Paliouras M, Diamandis EP.

Biol Chem. 2008 Jun;389(6):773-80. doi: 10.1515/BC.2008.072.

PMID:
18627304
16.

Expression and role of Foxa proteins in prostate cancer.

Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ.

Prostate. 2006 Jul 1;66(10):1013-28.

PMID:
16001449
17.

Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.

Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T.

J Urol. 2000 Sep;164(3 Pt 1):800-5.

PMID:
10953159
18.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
19.

Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.

Mashima T, Okabe S, Seimiya H.

Mol Pharmacol. 2010 Nov;78(5):846-54. doi: 10.1124/mol.110.064790. Epub 2010 Aug 13.

20.

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Taplin ME, Balk SP.

J Cell Biochem. 2004 Feb 15;91(3):483-90. Review.

PMID:
14755679
Items per page

Supplemental Content

Write to the Help Desk